| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting |
| 21 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 21, 2026, by and among AMBROS THERAPEUTICS, INC., a Delaware corporation (“Ambros”), WEREWOLF THERAPEUTICS, INC., a Delaware corporation (“Werewol... |
| 20 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with EMD Serono Research & Development Institute Inc. (“EMD”), pursuant to which, and sub... |
| 31 Jul 2026 |
8-K: Results of Operations and Financial Condition
Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engin... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
– Company continues to evaluate strategic options to maximize shareholder value – |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition
–Company continues to evaluate strategic options to maximize shareholder value - |
| 24 Feb 2026 |
8-K: Other Events
Watertown, MA, February 24, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the ... |
| 13 Feb 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
On February 9, 2026, the board of directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”) approved a reduction in force, representing 64% of the Company’s workforce (the “Reduction”). The Company expects the Reduction to b... |
| 06 Feb 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 18 Dec 2025 |
8-K: Other Events
Exhibit 99.1 Corporate Presentation December 2025 1 | ©2025 WEREWOLF THERAPEUTICS ©2025 WEREWOLF THERAPEUTICS |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – |
| 06 Oct 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – |
| 13 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
1.1 Place of Meetings. All meetings of stockholders shall be held at such place, if any, as may be designated from time to time by the Board of Directors, the Chair of the Board or the Chief Executive Officer or, if not so designated, at... |
| 15 May 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
©2025 WEREWOLF THERAPEUTICS1 | Delivering the Power of Immunotherapy CORPORATE PRESENTATION | May 2025 |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition
–Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respective... |
| 24 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockho... |
| 12 Nov 2024 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Delivering the Power of Immunotherapy CORPORATE PRESENTATION | November 2024 1 | ©2024 WEREWOLF THERAPEUTICS |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition; Other Events
–Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – |
Loading...